SNJ Pharma

SNJ Pharma is a South Korean pharmaceutical company specializing in the development of value-added "super-generic" drugs and advanced drug delivery systems. The company leverages its proprietary S-SMEDDS (Self-Super Micro Emulsifying Drug Delivery System) technology to improve the bioavailability and stability of poorly soluble active pharmaceutical ingredients. Their portfolio primarily focuses on chronic metabolic and cardiovascular diseases, including treatments for dyslipidemia and hypertension. SNJ Pharma aims to provide incrementally modified drugs (IMDs) that offer better patient compliance and therapeutic efficacy compared to standard generics. The company is actively expanding its pipeline through the development of fixed-dose combinations and optimized formulations for the global market.